FULC
NASDAQ · Pharmaceuticals
Fulcrum Therapeutics Inc
$3.71
-0.06 (-1.59%)
Financial Highlights (FY 2026)
Revenue
88.39M
Net Income
-10,744,616
Gross Margin
—
Profit Margin
-12.2%
Rev Growth
+61.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 34.6% | 34.6% |
| Operating Margin | -27.4% | -24.6% | 15.9% | 15.6% |
| Profit Margin | -12.2% | -11.6% | 12.9% | 11.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 88.39M | 54.89M | 366.88M | 363.96M |
| Gross Profit | — | — | 127.02M | 126.01M |
| Operating Income | -24,191,793 | -13,520,843 | 58.43M | 56.86M |
| Net Income | -10,744,616 | -6,005,188 | 47.13M | 41.26M |
| Gross Margin | — | — | 34.6% | 34.6% |
| Operating Margin | -27.4% | -24.6% | 15.9% | 15.6% |
| Profit Margin | -12.2% | -11.6% | 12.9% | 11.3% |
| Rev Growth | +61.0% | +61.0% | +22.0% | +14.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 278.39M | 348.66M |
| Total Equity | — | — | 429.92M | 514.10M |
| D/E Ratio | — | — | 0.65 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -8,984,663 | -5,300,521 | 69.95M | 74.03M |
| Free Cash Flow | — | — | 54.75M | 38.77M |